


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 31 AUGUST 2020 AND RETIREMENT OF DIRECTOR

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that the resolutions as set out in the Notice were duly passed by the Shareholders by way of poll at the Annual General Meeting held on 31 August 2020.

Reference is made to the circular (the “**Circular**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) and the Notice of the Annual General Meeting dated 31 July 2020 (the “**Notice**”) and the announcement (the “**Announcement**”) in relation to the notice of annual general meeting and circular dated 6 August 2020. Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that at the Annual General Meeting held on 31 August 2020, all the proposed ordinary resolutions as set out in the Notice (“**Ordinary Resolutions**”) were duly passed by the Shareholders by way of poll pursuant to Rule 13.39(4) of the Listing Rules.

Tricor Tengis Limited, the Company's branch share registrar, acted as the scrutineer for the purpose of the counting of votes at the Annual General Meeting. The poll results of the resolutions at the Annual General Meeting are as follows:

ORDINARY RESOLUTIONS		For		Against	
		Number of Shares	%	Number of Shares	%
1.	To receive and adopt the audited financial statements and the reports of the directors and of the auditors of the Company for the year ended 31 March 2020.	697,281,420	100	0	0
2.	(i) To re-elect Mr. Tang Rong as an executive Director;	697,281,420	100	0	0
	(ii) To re-elect Dr. Zhang Zhihong as an independent non-executive Director;	697,281,420	100	0	0
	(iii) To re-elect Ms. Huang He as an executive Director; and	/		/	
	(iv) To authorise the board of Directors to fix the Directors' remuneration.	697,281,420	100	0	0
3.	To re-appoint Elite Partners CPA Limited as the Company's auditors and to authorise the Board of Directors to fix their remuneration.	697,281,420	100	0	0
4.	To give a general mandate to the Directors to allot, issue and otherwise deal with additional Shares not exceeding 20% of the total number of the issued shares of the Company as at the date of this resolution.	697,281,420	100	0	0
5.	To give a general mandate to the Directors to buy back the Shares not exceeding 10% of the total number of the issued shares of the Company as at the date of this resolution.	697,281,420	100	0	0
6.	To extend the general mandate granted to the Directors to issue the Shares pursuant to the foregoing resolution no. 4 by a total number of Shares bought back by the Company pursuant to the foregoing resolution no. 5.	697,281,420	100	0	0

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions, the Ordinary Resolutions were duly passed by Shareholders by way of poll at the Annual General Meeting.

As at the date of the Annual General Meeting, a total of 1,464,193,024 Shares were in issue, which is the total number of Shares held by Shareholders entitled to attend and vote on all the proposed resolutions at the Annual General Meeting. No Shareholder was required under the Listing Rules to abstain from voting at the Annual General Meeting on any of the resolutions proposed thereat. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules.

RETIREMENT OF DIRECTOR

As stated in the Announcement, Ms. Huang He (“**Ms. Huang**”) retired as an executive Director at the conclusion of the AGM due to her intention to concentrate on her own business engagement. Ms. Huang has confirmed that she has no disagreement with the Board and there is no other matter in relation to her retirement that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Huang for her contribution to the Company during her tenure of office.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 31 August 2020

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).

Please also refer to the published version of this announcement on the Company’s website: www.ipb.asia and www.irasia.com/listco/hk/ipb.